CANbridge Pharmaceuticals Accelerates Drug Development

CANbridge Pharmaceuticals Inc. (HK:1228) has released an update.

CANbridge Pharmaceuticals Inc. reports significant headway in their drug pipeline for rare diseases, with the commercial launch of Hunterase® and Livmarli® in China and the progression of CAN103 through clinical trials. The company has also ventured into gene therapy, licensing a novel technology for Duchenne Muscular Dystrophy treatment, and expects to submit a New Drug Application for CAN103 by the end of 2024.

For further insights into HK:1228 stock, check out TipRanks’ Stock Analysis page.